Collaboration Needed to Develop Combination Cancer Therapies

More collaboration is needed if drugmakers are to overcome the unique regulatory and financial hurdles of co-developing agents for combination cancer therapies, according to a recent Institute of Medicine (IOM) report. When sponsors are reporting safety and efficacy trial data to the FDA, it can be difficult or impossible to measure and delineate the contribution of each agent to the safety and efficacy of the product, the IOM says in the recently published report to the National Cancer Institute.
Clinical Trials Advisor